{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:08:18Z","timestamp":1778674098511,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":2357,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Significant mitral regurgitation (MR) is an important predictor for all-cause mortality and heart failure (HF) hospitalizations independent of left ventricular ejection fraction (LVEF). The aims of this study were to investigate (i) in how many patients referred to a tertiary outpatient HF clinic HF therapy could be optimized, (ii) the effect of optimized treatment on MR severity, and (iii) whether a reduction in MR resulted in improvement of symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Forty-seven referred patients with therapy-resistant symptomatic chronic HF with an LVEF &amp;lt;40% and at least moderate MR were analysed on admission and after optimization of HF treatment after 6\u201318 months. The patients were classified as a volume responder when LV end-systolic volume (LVESV) decreased \u226515%, as LVEF responder when LVEF increased by \u22655% points, as clinical responder when New York Heart Association (NYHA) class improved at least one category, and as MR responder when MR severity improved at least one category to maximally moderate. After 14 \u00b1 4 months of treatment optimization, optimal doses of angiotensin-converting enzyme inhibitors\/angiotensin receptor blocker were seen in 18 (38%) patients compared with three (6%) at baseline (P &amp;lt; 0.001), and optimal doses of beta-blockers were seen in 14 (30%) patients compared with four (9%) at baseline (P &amp;lt; 0.001). In total, 68% of the patients were clinical responders, 57% MR responders, 34% volumetric responders, and 49% LVEF responders. NYHA class improved from 2.9 \u00b1 0.6 to 2.0 \u00b1 0.9 (P &amp;lt; 0.001), MR class from 5.2 \u00b1 0.8 to 3.6 \u00b1 1.5 (P &amp;lt; 0.001), LVEF from 24% \u00b1 9% to 31% \u00b1 12% (P &amp;lt; 0.01), and LVESV non-significantly improved. The positive predictive value of MR response to NYHA response was 88%; the negative predictive value was 53%, agreement 69%, and kappa 0.39. The positive predictive value of LVEF response to NYHA response was 76%; the negative predictive value was 44%, agreement 60%, and kappa 0.21. The positive predictive value of LVESV volume response to NYHA response was 75%; the negative predictive value was 39%, agreement 51%, and kappa 0.12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although this study was limited by a small number of patients, initiation and up-titration of recommended HF therapy in patients referred to our tertiary HF outpatient clinic resulted in significant MR reduction in over half of the patients, emphasizing the importance of optimal medical treatment in these very sick cardiac patients with otherwise grave prognosis. MR reduction was best correlated to NYHA improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12478","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T08:36:26Z","timestamp":1565166986000},"page":"936-943","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evolution of Mitral Regurgitation in Patients with Heart Failure Referred to a Tertiary Heart Failure Clinic"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9821-9569","authenticated-orcid":false,"given":"Lotte E.","family":"de Groot \u2013 de Laat","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessy","family":"Huizer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattie","family":"Lenzen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel L.","family":"Geleijnse","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadir","family":"Caliskan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"2026012115090223000_ehf212478-bib-0001","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/hrt.2011.225789","article-title":"Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy","volume":"97","author":"Rossi","year":"2011","journal-title":"Heart"},{"key":"2026012115090223000_ehf212478-bib-0002","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115090223000_ehf212478-bib-0003","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0002-8703(00)90036-X","article-title":"Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol","volume":"139","author":"Capomolla","year":"2000","journal-title":"Am Heart J"},{"key":"2026012115090223000_ehf212478-bib-0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0041-1345(01)02717-8","article-title":"Effect of carvedilol therapy on functional mitral regurgitation, ventricular remodeling, and contractility in patients with heart failure due to left ventricular systolic dysfunction","volume":"34","author":"Comin-Colet","year":"2002","journal-title":"Transplant Proc"},{"key":"2026012115090223000_ehf212478-bib-0005","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(99)00059-4","article-title":"Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure","volume":"83","author":"Lowes","year":"1999","journal-title":"Am J Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0006","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1388-9842(03)00105-3","article-title":"Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy","volume":"5","author":"Waagstein","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026012115090223000_ehf212478-bib-0007","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0002-9149(98)00623-7","article-title":"Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling","volume":"82","author":"Levine","year":"1998","journal-title":"Am J Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0008","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/0002-9149(87)90376-6","article-title":"Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"60","author":"Stevenson","year":"1987","journal-title":"Am J Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0009","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.108.818724","article-title":"Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I\/II heart failure","volume":"120","author":"St John Sutton","year":"2009","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0010","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000065226.24159.E9","article-title":"Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure","volume":"107","author":"St John Sutton","year":"2003","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0011","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2007.08.019","article-title":"Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation","volume":"50","author":"Ypenburg","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0012","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0735-1097(02)02937-6","article-title":"Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure","volume":"41","author":"Breithardt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0013","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.112.000112","article-title":"Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome","volume":"6","author":"Onishi","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026012115090223000_ehf212478-bib-0014","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1161\/CIRCULATIONAHA.110.009803","article-title":"Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk","volume":"124","author":"van Bommel","year":"2011","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ehjci\/jet105","article-title":"Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115090223000_ehf212478-bib-0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115090223000_ehf212478-bib-0017","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012115090223000_ehf212478-bib-0018","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"Group CTS","year":"1987","journal-title":"N Engl J Med"},{"key":"2026012115090223000_ehf212478-bib-0019","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees","volume":"90","author":"A randomized trial of beta-blockade in heart failure","year":"1994","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026012115090223000_ehf212478-bib-0021","first-page":"196","article-title":"Has beta-blocker use increased in patients with heart failure in internal medicine settings? Prognostic implications: RICA registry","volume":"67","author":"Gonzalez-Garcia","year":"2014","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026012115090223000_ehf212478-bib-0022","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ahj.2015.10.026","article-title":"Discharge heart rate and beta-blocker dose in patients hospitalized with heart failure: findings from the OPTIMIZE-HF registry","volume":"173","author":"DeVore","year":"2016","journal-title":"Am Heart J"},{"key":"2026012115090223000_ehf212478-bib-0023","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115090223000_ehf212478-bib-0024","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1161\/01.CIR.103.13.1759","article-title":"Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment","volume":"103","author":"Grigioni","year":"2001","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/01.CIR.0000087599.49332.05","article-title":"Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction","volume":"108","author":"Lancellotti","year":"2003","journal-title":"Circulation"},{"key":"2026012115090223000_ehf212478-bib-0026","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.amjcard.2011.07.045","article-title":"Impact of mitral regurgitation on exercise capacity and clinical outcomes in patients with ischemic left ventricular dysfunction","volume":"108","author":"Szymanski","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0027","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.amjcard.2015.01.549","article-title":"Early improvement of functional mitral regurgitation in patients with idiopathic dilated cardiomyopathy","volume":"115","author":"Stolfo","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026012115090223000_ehf212478-bib-0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCIMAGING.111.966580","article-title":"Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy","volume":"5","author":"Verhaert","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012115090223000_ehf212478-bib-0029","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115090223000_ehf212478-bib-0030","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Kang","year":"2019","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12478","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/5\/936\/66136461\/eschf_6_5_936.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/6\/5\/936\/66136461\/eschf_6_5_936.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:11:40Z","timestamp":1769026300000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/6\/5\/936\/8403525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,8,7]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12478","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"2018-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}